Anti-EMP2 diabody blocks epithelial membrane protein 2 (EMP2) and FAK mediated collagen gel contraction in ARPE-19 cells

Experimental Eye Research

Volumn 102, Issue , 2012, Pages 10-16

  Morales, Shawn A ^a   Telander, David G ^b   Mareninov, Sergey ^a   Nagy, Agnes ^c   Wadehra, Madhuri ^a   Braun, Jonathan ^a   Gordon, Lynn K ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Antibody; Retinal pigment epithelium; Signal transduction

Indexed keywords

COLLAGEN GEL; COLLAGEN TYPE 1; EPITHELIAL MEMBRANE PROTEIN 2; FOCAL ADHESION KINASE; MEMBRANE PROTEIN; TOLONIUM CHLORIDE; UNCLASSIFIED DRUG; VISUAL PIGMENT;

ARTICLE; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; IN VITRO STUDY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTIBODIES, BLOCKING; ANTIGEN-ANTIBODY REACTIONS; APOPTOSIS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL LINE; CELL MOVEMENT; COLLAGEN TYPE I; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FOCAL ADHESION KINASE 1; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MEMBRANE GLYCOPROTEINS; MICROSCOPY, CONFOCAL; PEPTIDE LIBRARY; RETINAL PIGMENT EPITHELIUM; SINGLE-CHAIN ANTIBODIES;

EID: 84865584816     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2012.06.002     Document Type: Article

References (45)

1. Al-Khairi A.M., Al-Kahtani E., Kangave D., Abu El-Asrar A.M. Prognostic factors associated with outcomes after giant retinal tear management using perfluorocarbon liquids. Eur. J. Ophthalmol. 2008, 18:270-277.
2. Asaria R.H., Gregor Z.J. Simple retinal detachments: identifying the at-risk case. Eye 2002, 16:404-410.
3. Bonnet M., Fleury J. Management of retinal detachment after penetrating eye injury. Graefes Arch. Clin. Exp. Ophthalmol. 1991, 229:539-542.
4. Calalb M.B., Polte T.R., Hanks S.K. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol. Cell Biol. 1995, 15:954-963.
5. Campochiaro P.A. Pathogenic mechanisms in proliferative vitreoretinopathy. Arch. Ophthalmol. 1997, 115:237-241.
6. Cardillo J.A., Stout J.T., LaBree L., Azen S.P., Omphroy L., Cui J.Z., Kimura H., Hinton D.R., Ryan S.J. Post-traumatic proliferative vitreoretinopathy. The epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology 1997, 104:1166-1173.
7. Charteris D.G., Sethi C.S., Lewis G.P., Fisher S.K. Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye 2002, 16:369-374.
8. Colyer M.H., Weber E.D., Weichel E.D., Dick J.S., Bower K.S., Ward T.P., Haller J.A. Delayed intraocular foreign body removal without endophthalmitis during Operations Iraqi Freedom and Enduring Freedom. Ophthalmology 2007, 114:1439-1447.
9. Forbes A., Wadehra M., Mareninov S., Morales S., Shimazaki K., Gordon L.K., Braun J. The tetraspan protein EMP2 regulates expression of caveolin-1. J. Biol. Chem. 2007, 282:26542-26551.
10. Fu M., Maresh E.L., Soslow R.A., Alavi M., Mah V., Zhou Q., Iasonos A., Goodglick L., Gordon L.K., Braun J., Wadehra M. Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer. Clin. Cancer Res. 2010, 16:3954-3963.
11. Glaser B.M., Cardin A., Biscoe B. Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction. Ophthalmology 1987, 94:327-332.
12. Grierson I., Mazure A., Hogg P., Hiscott P., Sheridan C., Wong D. Non-vascular vitreoretinopathy: the cells and the cellular basis of contraction. Eye 1996, 10(Pt 6):671-684.
13. Hemler M.E. Tetraspanin functions and associated microdomains. Nat. Rev. Mol. Cell Biol. 2005, 6:801-811.
14. Hinton D.R., He S., Jin M.L., Barron E., Ryan S.J. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye 2002, 16:422-428.
15. Holliger P., Prospero T., Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. U S A 1993, 90:6444-6448.
16. Hueber A., Esser P., Heimann K., Kociok N., Winter S., Weller M. The topoisomerase I inhibitors, camptothecin and beta-lapachone, induce apoptosis of human retinal pigment epithelial cells. Exp. Eye Res. 1998, 67:525-530.
17. James M., O'Doherty M., Beatty S. The prognostic influence of chronicity of rhegmatogenous retinal detachment on anatomic success after reattachment surgery. Am. J. Ophthalmol. 2007, 143:1032-1034.
18. Jin M., He S., Worpel V., Ryan S.J., Hinton D.R. Promotion of adhesion and migration of RPE cells to provisional extracellular matrices by TNF-alpha. Invest. Ophthalmol. Vis. Sci. 2000, 41:4324-4332.
19. Kirchhof B. Strategies to influence PVR development. Graefes Arch. Clin. Exp. Ophthalmol. 2004, 242:699-703.
20. Kruger E.F., Nguyen Q.D., Ramos-Lopez M., Lashkari K. Proliferative vitreoretinopathy after trauma. Int. Ophthalmol. Clin. 2002, 42:129-143.
21. Levy S., Shoham T. Protein-protein interactions in the tetraspanin web. Physiology (Bethesda) 2005, 20:218-224.
22. Levy S., Shoham T. The tetraspanin web modulates immune-signalling complexes. Nat. Rev. Immunol. 2005, 5:136-148.
23. Marks J.D., Bradbury A. Selection of human antibodies from phage display libraries. Methods Mol. Biol. 2004, 248:161-176.
24. Morales S.A., Mareninov S., Coulam P., Wadehra M., Goodglick L., Braun J., Gordon L.K. Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2). Invest. Ophthalmol. Vis. Sci. 2009, 50:4949-4956.
25. Morales S.A., Mareninov S., Prasad P., Wadehra M., Braun J., Gordon L.K. Collagen gel contraction by ARPE-19 cells is mediated by a FAK-Src dependent pathway. Exp. Eye Res. 2007, 85:790-798.
26. Morales S.A., Mareninov S., Wadehra M., Zhang L., Goodglick L., Braun J., Gordon L.K. FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction. Invest. Ophthalmol. Vis. Sci. 2009, 50:462-469.
27. Mukherjee S., Guidry C. The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation. Invest. Ophthalmol. Vis. Sci. 2007, 48:1892-1899.
28. Nair A.R., Schliekelman M., Thomas M.B., Wakefield J., Jurgensen S., Ramabhadran R. Inhibition of p53 by lentiviral mediated shRNA abrogates G1 arrest and apoptosis in retinal pigmented epithelial cell line. Cell Cycle 2005, 4:697-703.
29. Olafsen T., Cheung C.W., Yazaki P.J., Li L., Sundaresan G., Gambhir S.S., Sherman M.A., Williams L.E., Shively J.E., Raubitschek A.A., Wu A.M. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng. Des Sel 2004, 17:21-27.
30. Sakamoto T., Hinton D.R., Sakamoto H., Oganesian A., Kohen L., Gopalakrishna R., Ryan S.J. Collagen gel contraction induced by retinal pigment epithelial cells and choroidal fibroblasts involves the protein kinase C pathway. Curr. Eye Res. 1994, 13:451-459.
31. Schlaepfer D.D., Hauck C.R., Sieg D.J. Signaling through focal adhesion kinase. Prog. Biophys. Mol. Biol. 1999, 71:435-478.
32. Schlaepfer D.D., Hunter T. Integrin signalling and tyrosine phosphorylation: just the FAKs?. Trends Cell Biol. 1998, 8:151-157.
33. Shimada H., Fujita K., Matsumoto Y., Mori R., Yuzuwa M. Preoperative factors influencing visual outcome following surgical excision of subfoveal choroidal. Eur. J. Ophthalmol. 2006, 16:287-294.
34. Shimazaki K., Lepin E.J., Wei B., Nagy A.K., Coulam C.P., Mareninov S., Fu M., Wu A.M., Marks J.D., Braun J., Gordon L.K., Wadehra M. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin. Cancer Res. 2008, 14:7367-7377.
35. Sobaci G., Akyn T., Mutlu F.M., Karagul S., Bayraktar M.Z. Terror-related open-globe injuries: a 10-year review. Am. J. Ophthalmol. 2005, 139:937-939.
36. Sobaci G., Mutlu F.M., Bayer A., Karagul S., Yildirim E. Deadly weapon-related open-globe injuries: outcome assessment by the ocular trauma classification system. Am. J. Ophthalmol. 2000, 129:47-53.
37. Sparrow J.R., Hicks D., Hamel C.P. The retinal pigment epithelium in health and disease. Curr. Mol. Med. 2010, 10:802-823.
38. Telander D.G., Morales S.A., Mareninov S., Forward K., Gordon L.K. Epithelial membrane protein-2 (EMP2) and experimental proliferative vitreoretinopathy (PVR). Curr. Eye Res. 2011, 36:546-552.
39. Wadehra M., Forbes A., Pushkarna N., Goodglick L., Gordon L.K., Williams C.J., Braun J. Epithelial membrane protein-2 regulates surface expression of alphavbeta3 integrin in the endometrium. Dev. Biol. 2005, 287:336-345.
40. Wadehra M., Goodglick L., Braun J. The tetraspan protein EMP2 modulates the surface expression of caveolins and glycosylphosphatidyl inositol-linked proteins. Mol. Biol. Cell 2004, 15:2073-2083.
41. Wadehra M., Iyer R., Goodglick L., Braun J. The tetraspan protein epithelial membrane protein-2 interacts with beta1 integrins and regulates adhesion. J. Biol. Chem. 2002, 277:41094-41100.
42. Wadehra M., Mainigi M., Morales S.A., Rao R.G., Gordon L.K., Williams C.J., Braun J. Steroid hormone regulation of EMP2 expression and localization in the endometrium. Reprod. Biol. Endocrinol. 2008, 6:15.
43. Wadehra M., Su H., Gordon L.K., Goodglick L., Braun J. The tetraspan protein EMP2 increases surface expression of class I major histocompatibility complex proteins and susceptibility to CTL-mediated cell death. Clin. Immunol. 2003, 107:129-136.
44. Wadehra M., Sulur G.G., Braun J., Gordon L.K., Goodglick L. Epithelial membrane protein-2 is expressed in discrete anatomical regions of the eye. Exp. Mol. Pathol. 2003, 74:106-112.
45. Wang C.X., Wadehra M., Fisk B.C., Goodglick L., Braun J. Epithelial membrane protein 2, a 4-transmembrane protein that suppresses B-cell lymphoma tumorigenicity. Blood 2001, 97:3890-3895.